Filing Details

Accession Number:
0000950170-24-002278
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-01-04 21:47:38
Reporting Period:
2024-01-02
Accepted Time:
2024-01-04 21:47:38
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1818794 Dyne Therapeutics Inc. DYN Pharmaceutical Preparations (2834) 364883909
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1824673 Jonathan Mcneill 1560 Trapelo Road
Waltham MA 02451
Chief Business Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2024-01-02 11,900 $13.10 143,618 No 4 S Direct
Common Stock Acquisiton 2024-01-03 17,991 $0.73 161,609 No 4 M Direct
Common Stock Disposition 2024-01-03 7,691 $18.34 153,918 No 4 S Direct
Common Stock Disposition 2024-01-03 10,300 $19.03 143,618 No 4 S Direct
Common Stock Acquisiton 2024-01-04 2,009 $0.73 145,627 No 4 M Direct
Common Stock Disposition 2024-01-04 2,009 $18.04 143,618 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock option (right to buy) Disposition 2024-01-03 17,991 $0.00 17,991 $0.73
Common Stock Stock option (right to buy) Disposition 2024-01-04 2,009 $0.00 2,009 $0.73
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
50,537 2029-02-25 No 4 M Direct
48,528 2029-02-25 No 4 M Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $12.76 to $13.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes of this Form 4.
  3. Includes 143,067 unvested RSUs.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.00 to $18.50, inclusive.
  5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $19.00 to $19.25, inclusive.
  6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.00 to $18.07, inclusive.
  7. The option was granted on February 26, 2019. The shares underlying the option vest over four years, with 25% of the shares vesting on February 1, 2020 and the remaining shares vesting in equal quarterly installments thereafter.